摘要
目的:探究重组牛碱性成纤维细胞生长因子滴眼液(商品名:贝复舒)联合奥洛他定滴眼液在过敏性结膜炎中的应用效果。方法:选取苏州市第九人民医院2019年7月-2022年6月收治的过敏性结膜炎患者115例作为研究对象,采用随机数字表法将其分为对照组(n=58)和研究组(n=57)。对照组予以奥洛他定滴眼液治疗,研究组予以贝复舒与奥洛他定滴眼液联合治疗。比较两组疗效、炎症水平、免疫水平、泪膜稳定性及药物不良反应的发生情况。结果:研究组疗效明显优于对照组(P<0.05)。治疗前,两组嗜酸性粒细胞阳离子蛋白(ECP)、超敏C反应蛋白(hs-CRP)、白细胞介素-10(IL-10)水平比较,差异均无统计学意义(P>0.05);治疗后,两组ECP、hs-CRP水平均较治疗前明显下降(P<0.05),研究组均明显低于对照组(P<0.05);两组IL-10水平均较治疗前明显上升(P<0.05),研究组明显高于对照组(P<0.05)。治疗前,两组免疫球蛋白A(IgA)、免疫球蛋白E(IgE)水平比较,差异均无统计学意义(P>0.05);治疗后,两组IgA、IgE水平均较治疗前明显下降(P<0.05),研究组均明显低于对照组(P<0.05)。治疗前,两组泪膜破裂时间(BUT)、角膜荧光素染色评分、泪液分泌试验比较,差异均无统计学意义(P>0.05);治疗后,两组角膜荧光素染色评分均较治疗前下降,研究组明显低于对照组(P<0.05),泪液分泌试验均较治疗前增加,研究组高于对照组(P<0.05);两组BUT水平均较治疗前明显上升(P<0.05),研究组明显高于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:对过敏性结膜炎患者应用重组牛碱性成纤维细胞生长因子滴眼液与奥洛他定滴眼液联合治疗,效果显著,炎症及免疫水平有明显改善,同时可提高泪膜稳定性,不增加用药不良反应,安全可控。
Objective:To investigate the application effect of Recombinant Bovine Basic Fibroblast Growth Factor Eye Drops(trade name:Beifushu)combined with Olopatadine Eye Drops in allergic conjunctivitis.Method:A total of one hundred and fifteen patients with allergic conjunctivitis admitted to Suzhou Ninth People's Hospital between July 2019 and June 2022 were selected for this study and divided into control group(n=58)and study group(n=57)by random number table method.The control group was treated with Olopatadine Eye Drops,the study group was treated with Beifushu in combination with Olofadine Eye Drops.The efficacy,inflammatory level,immune level,tear film stability and occurrence of adverse drug reactions were compared between the two groups.Result:The efficacy of the study group was significantly better than that of the control group(P<0.05).Before treatment,there were no significant differences in the levels of eosinophil cationic protein(ECP),hypersensitivity c reactive protein(hs-CRP),and interleukin-10(IL-10)between the two groups(P>0.05);after treatment,the levels of ECP and hs-CRP in the two groups were significantly decreased compared with those before treatment(P<0.05),the study group were significantly lower than those of the control group(P<0.05);the levels of IL-10 in the two groups increased significantly compared with those before treatment(P<0.05),the study group was significantly higher than that of the control group(P<0.05).Before treatment,there were no statistically significant differences in the levels of immunoglobulin A(IgA)and immunoglobulin E(IgE)between the two groups(P>0.05);after treatment,the levels of IgA and IgE in both groups decreased significantly compared with those before treatment(P<0.05),the study group were significantly higher than those in the control group(P<0.05).Before treatment,there were no statistically significant differences in tear film break up time(BUT),corneal fluorescein staining scores and tear secretion test between the two groups(P>0.05);after treatment,the corneal fluorescein staining scores decreased significantly compared with those before treatment(P<0.05),and tear secretion test significant increase compared with those before treatment(P<0.05),the study group were significantly higher than those in the control group(P<0.05);the levels of BUT in the two groups increased significantly compared with that before treatment(P<0.05),the study group was significantly higher than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combined treatment of Recombinant Bovine Basic Fibroblast Growth Factor Eye Drops and Olofatadine Eye Drops in patients with allergic conjunctivitis has significant effects,significantly improving the levels of inflammation and immunity,and improving the stability of tear film without increasing adverse drug reactions,which is safe and controllable.
作者
孙尉
荣飞
SUN Wei;RONG Fei(Suzhou Ninth People's Hospital,Jiangsu Province,Suzhou 215200,China;不详)
出处
《中国医学创新》
CAS
2023年第16期150-154,共5页
Medical Innovation of China
